期刊
DIAGNOSTICS
卷 11, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/diagnostics11071195
关键词
endoscopic ultrasound-guided tissue acquisition; endoscopic ultrasound-guided fine needle aspiration; endoscopic ultrasound-guided fine needle biopsy; next-generation sequencing; precision medicine; pancreatic cancer; chemotherapy; biomarker; targeted genome sequencing
Precision medicine in cancer treatment involves targeted therapy based on biomarker evaluation. Despite the challenges in pancreatic cancer, novel biomarker-based therapies have emerged, identifying potential genetic alterations as therapeutic targets in patients with PC.
Precision medicine in cancer treatment refers to targeted therapy based on the evaluation of biomarkers. Although precision medicine for pancreatic cancer (PC) remains challenging, novel biomarker-based therapies, such as pembrolizumab, olaparib, and entrectinib, have been emerging. Most commonly, endoscopic ultrasound-guided tissue acquisition (EUS-TA) had been used for the diagnosis of PC until now. However, advances in EUS-TA devices and biomarker testing, especially next-generation sequencing, have opened up the possibility of sequencing of various genes even in limited amounts of tissue samples obtained by EUS-TA, and identifying potential genetic alterations as therapeutic targets. Precision medicine benefits only a small population of patients with PC, but biomarker-based therapy has shown promising results in patients who once had no treatment options. Now, the role of EUS-TA has extended beyond diagnosis into decision-making regarding the treatment of PC. In this review, we mainly discuss tissue sampling by EUS-TA for biomarker testing and the current status of precision medicine for PC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据